G protein-coupled receptor 39 (GPR39)

G protein-coupled receptor 39 (GPR39) is a member of the ghrelin receptor family and functions as a zinc-sensing receptor that transduces changes in extracellular Zn^2+ into cellular responses via classic G protein-coupled signaling cascades[1][3][10]. It is a seven-transmembrane, rhodopsin-like GPCR highly conserved among vertebrates, with prominent expression in the gastrointestinal tract, pancreas, skin, adipose tissue, heart, vascular endothelium, brain, and reproductive tissues[1][3][5][9]. Upon stimulation by zinc or synthetic agonists, GPR39 activates multiple pathways (ERK/MAPK, PI3K/AKT, PKC/MAPK/CEBPB), promoting epithelial repair, wound healing, cell survival, ion homeostasis, glucose regulation, and anti-inflammatory as well as antioxidant effects[1][3][5][10][11]. Preclinical evidence implicates GPR39 in diverse disease processes, including gastrointestinal dysfunction, neurodegenerative diseases, cardiovascular pathology (notably hypertension), obesity, diabetes, and several cancers[2][5][6][7][8]. GPR39 is under active investigation as a drug target, with synthetic agonists such as TC-G-1008 and others in preclinical development[2][4][7]. However, significant therapeutic challenges remain, including concerns about potential oncogenic effects, context-dependent signaling, impact of zinc status, and limited clinical safety data[2][4]. There are no approved drugs targeting GPR39, nor is there robust evidence of established clinical biomarkers or patient selection strategies in routine use at this time[2].

Other names

Zinc-sensing receptorZnRGPR39-1a (canonical isoform)GPR39-1b (splice variant)

Orthosteric or allosteric agonism (primarily by Zn^2+); Positive allosteric modulation by zinc; Activation of ERK/MAPK and PI3K/AKT signaling pathways; Modulation of ion transport and cell signaling through G-protein dependent pathways.